If hospitals were able to incorporate rapidly evolving clinical evidence into institutional guidelines during the COVID crisis, how might that kind of nimble response inform treatment of other conditions?
in men and individuals on anticoagulation prior to being infected were protected against this. and we found bleeding was a two fold increase and this risk was increased for two months and this was higher in men. when we look in more severe disease, so that that needed but those that needed hospitalisation or intensive care, these risks were much higher. and interestingly, those individuals who had mild covid 19 and it means they did not need hospitalisation, they did not need hospitalisation, they did not need hospitalisation, they did not have an increased risk of bleeding, which could be due to the fact that severe cases had more severe disease information or it could be a side effect that individuals were hospitalised or needed intensive care. this individuals were hospitalised or needed intensive care.- individuals were hospitalised or needed intensive care. as you can imarine, needed intensive care. as you can imagine. this needed intensive care. as you can imagine, this may
The ADAPT-TAVR trial showed a numerical reduction in leaflet thrombosis with edoxaban versus dual antiplatelet therapy, but no reduction in cerebral events or neurocognitive function